Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up Following Analyst Upgrade

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up before the market opened on Monday after China Intl Cap upgraded the stock to a strong-buy rating. The stock had previously closed at $26.28, but opened at $27.24. Ascentage Pharma Group International shares last traded at $27.6240, with a volume of 3,340 shares.

Other equities analysts also recently issued research reports about the stock. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Finally, Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $48.00.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds have recently bought and sold shares of the company. XY Capital Ltd boosted its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Finally, ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $204,000.

Ascentage Pharma Group International Stock Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The stock’s 50 day moving average is $24.01 and its 200 day moving average is $29.08.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million for the quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.